中国医药科学2016，Vol.6Issue(22)：42-44,3.
利福喷丁与利福平在肺结核治疗中的药效比较及安全性分析
Efficacy comparison and safety analysis of rifapentine and rifampicin in treatment of patients with pulmonary tuberculosis
周佳宇1
作者信息
- 1. 北京市房山区疾病预防控制中心结核科，北京 102488
- 折叠
摘要
Abstract
Objective To investigate the efficacy and safety of rifapentine and rifampicin in the treatment of pulmonary tuberculosis from June 2014 to June 2016. Methods 150 cases of patients with pulmonary tuberculosis from our center were selected as the study objects. including 75 cases with rifapentine therapy, 75 cases with rifampicin treatment. Six months after the therapy, the therapeutic effect and adverse drug reaction of the two groups were compared and analyzed. Results After six months of treatment, the sputum bacteriology negative rate, lesions absorption rate and cavity closure rate, the effective rate of the rifapentine group were slightly higher than those of rifampicin group, and the difference was not statistically significant (P > 0.05). The adverse reaction rate of rifapentine group rifapentine group was significantly lower than that in rifampicin group, the difference was statistically significant (P < 0.05). Conclusion The curative effect of rifapentine in the treatment of pulmonary tuberculosis is significant. The adverse reaction rate is low, and it has high clinical value. It is worthy of promotion.关键词
利福喷丁/利福平/肺结核/药效/安全性Key words
Rifapentine/Rifampicin/Pulmonary tuberculosis/Efficacy/Safety分类
医药卫生引用本文复制引用
周佳宇..利福喷丁与利福平在肺结核治疗中的药效比较及安全性分析[J].中国医药科学,2016,6(22):42-44,3.
